Valeant wins Salix bidding war; Thiel invests in biotech;

@FierceBiotech: Cidara Therapeutics makes a quick leap into the growing Q1 IPO queue. News | Follow @FierceBiotech

@JohnCFierce: We're up to about 600 responses to our bull vs. bubble survey. Today's your last shot at participating. Survey | Follow @JohnCFierce

@DamianFierce: Fun fact: The NEJM paper that got PCSK9 blockade rolling was published just nine years ago. Paper | Follow @DamianFierce

> Valeant ($VRX) beat Endo ($ENDP) in a showdown for Salix Pharmaceuticals ($SLXP), agreeing to pay $173 per share in cash, or about $15.8 billion, for the North Carolina drugmaker. Story

> Silicon Valley billionaire Peter Thiel has been quietly investing in biotech startups, backing firms he believes are more than just "a lottery ticket" that's unlikely to pan out. More

> Y Combinator is backing a startup called Notable Labs that uses data analytics and robotics to spotlight potentially helpful combinations of existing drugs. Item

Medical Device News

@FierceMedDev: Metabolon rides on last year's success with $5M in extended financing. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: FDA expands indication of the only sublingual second-gen antipsychotic. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Metabolon rides on last year's success with $5M in extended financing. Story | Follow @EmilyWFierce

> St. Jude releases promising data on its heart failure system. Article

> Edwards and Medtronic turn up TAVR competition with positive study data. News

Pharma News

@FiercePharma: ICYMI Friday: England to provide $GSK MenW vaccine to 3 million teens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: GAO says FDA and DEA need to play better. The 2 can't even agree on what constitutes a drug shortage. FiercePharmaManufactuing article | Follow @EricPFierce

@CarlyHFierce: Endo Withdraws Proposal for Salix. Release | Follow @CarlyHFierce

> Can AstraZeneca expect big things from long-awaited Brilinta data? Maybe not, analysts say. Story

> Sorry, Endo. Valeant's back on top with $173-per-share Salix bid. Report

Animal Health News

> Aratana Therapeutics reports lower Q4, full-year 2014 financials. News

> USDA to launch national equine study this spring. Item

> Hedge fund snaps up 5% of Valeant amid speculation of a Zoetis deal. More

> New FDA report finds banned antibiotics still showing up in dairy cow tests. Story

> USDA head calls halt to any new experiments at Nebraska facility. Article

Biotech IT News

> Y Combinator backs cancer drug combo testing service. Story

> Genomics England doles out $12M as sequencing yields early breakthroughs. More

> Google adds Tute database to burgeoning Genomics platform. Report

> UCB to host epilepsy digital tool hackathon. Item

> Apple turns 700M iPhone users into potential participants in massive virtual trials. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.